Serum C18:1-Cer as a Potential Biomarker for Early Detection of Gestational Diabetes

• Published in: Journal of clinical medicine Vol. 11; no. 2; p. 384
• Main Authors: Juchnicka, Ilona, Kuźmicki, Mariusz, Zabielski, Piotr, Krętowski, Adam, Błachnio-Zabielska, Agnieszka, Szamatowicz, Jacek
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.01.2022; MDPI
• Subjects: Clinical medicine; Insulin resistance; Kinases; Lipids; Womens health; United States > US; Switzerland; Germany; lipidomic; C18:1-Cer; sphingolipids; gestational diabetes; ceramides
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11020384

We hypothesized that sphingolipids may be early biomarkers of gestational diabetes mellitus (GDM). Here, 520 women with normal fasting plasma glucose levels were recruited in the first trimester and tested with a 75 g oral glucose tolerance test in the 24th-28th week of pregnancy. Serum sphingolipids concentrations were measured in the first and the second trimester by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC/MS/MS) in 53 patients who were diagnosed with GDM, as well as 82 pregnant women with normal glucose tolerance (NGT) and 32 non-pregnant women. In the first trimester, pregnant women showed higher concentrations of C16:0, C18:1, C22:0, C24:1, and C24:0-Cer and lower levels of sphinganine (SPA) and sphingosine-1-phosphate (S1P) compared to non-pregnant women. During pregnancy, we observed significant changes in C16:0, C18:0, C18:1, and C24:1-Cer levels in the GDM group and C18:1 and C24:0-Cer in NGT. The GDM (pre-conversion) and NGT groups in the first trimester differed solely in the levels of C18:1-Cer (AUC = 0.702 = 0.008), also considering glycemia. Thus, C18:1-Cer revealed its potential as a GDM biomarker. Sphingolipids are known to be a modulator of insulin resistance, and our results indicate that ceramide measurements in early pregnancy may help with GDM screening.